{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:35:00Z","timestamp":1791329700576,"version":"4.3.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pediatric-onset Multiple Sclerosis (POMS) patients show more inflammatory disease compared with adult-onset MS. However, highly effective treatments are limited with only fingolimod being approved in Italy and natalizumab prescribed as off-label treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>to compare the efficacy of natalizumab versus fingolimod in POMS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is an observational longitudinal multicentre study including natalizumab- and fingolimod-treated POMS patients (N-POMS and F-POMS, respectively). We collected Annual Relapse Rate (ARR), Expanded Disability Status Scale (EDSS), Symbol Digit Modality Test (SDMT), and MRI activity at baseline (T0), 12\u201318\u00a0months (T1), and last available observation (T2).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We enrolled 57 N-POMS and 27 F-POMS patients from six Italian MS Centres. At T0, N-POMS patients showed higher ARR (<jats:italic>p<\/jats:italic>\u2009=\u20090.03), higher EDSS (<jats:italic>p<\/jats:italic>\u2009=\u20090.003) and lower SDMT (<jats:italic>p<\/jats:italic>\u2009=\u20090.04) at baseline compared with F-POMS. Between T<jats:sub>0<\/jats:sub> and T<jats:sub>1<\/jats:sub> ARR improved for both N-POMS and F-POMS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), while EDSS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and SDMT (<jats:italic>p<\/jats:italic>\u2009=\u20090.03) improved only for N-POMS. At T<jats:sub>2<\/jats:sub> (66.1\u2009\u00b1\u200955.4\u00a0months) we collected data from 42 out of 57 N-POMS patients showing no further ARR decrease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Both natalizumab and fingolimod showed high and sustained efficacy in controlling relapses and natalizumab also associated to a disability decrease in POMS. This latter effect might be partly mediated by the high inflammatory activity at baseline in N-POMS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-024-12610-y","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T22:55:32Z","timestamp":1724453732000},"page":"6773-6781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod"],"prefix":"10.1007","volume":"271","author":[{"given":"Antonio","family":"Carotenuto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Di Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Papetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Borriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Signoriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Masciulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ianniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Lus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Novarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Luca","family":"Spiezia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Di Somma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Petracca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Iacovazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Servillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Portaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Triassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Valeriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"12610_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/0883073819845827","volume":"34","author":"A Jeong","year":"2019","unstructured":"Jeong A, Oleske DM, Holman J (2019) Epidemiology of pediatric-onset multiple sclerosis: a systematic review of the literature. J Child Neurol 34:705\u2013712. https:\/\/doi.org\/10.1177\/0883073819845827","journal-title":"J Child Neurol"},{"key":"12610_CR2","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa067597","volume":"356","author":"C Renoux","year":"2007","unstructured":"Renoux C, Vukusic S, Mikaeloff Y et al (2007) Natural history of multiple sclerosis with childhood onset. N Engl J Med 356:2603\u20132613. https:\/\/doi.org\/10.1056\/NEJMoa067597","journal-title":"N Engl J Med"},{"key":"12610_CR3","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1093\/brain\/awp278","volume":"132","author":"EA Yeh","year":"2009","unstructured":"Yeh EA, Weinstock-Guttman B, Ramanathan M et al (2009) Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain 132:3392\u20133400. https:\/\/doi.org\/10.1093\/brain\/awp278","journal-title":"Brain"},{"key":"12610_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S2352-4642(18)30026-9","volume":"2","author":"G Fadda","year":"2018","unstructured":"Fadda G, Brown RA, Longoni G et al (2018) MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health 2:191\u2013204. https:\/\/doi.org\/10.1016\/S2352-4642(18)30026-9","journal-title":"Lancet Child Adolesc Health"},{"key":"12610_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40263-021-00887-w","volume":"36","author":"D Jakimovski","year":"2022","unstructured":"Jakimovski D, Awan S, Eckert SP et al (2022) Multiple sclerosis in children: differential diagnosis, prognosis, and disease-modifying treatment. CNS Drugs 36:45\u201359. https:\/\/doi.org\/10.1007\/s40263-021-00887-w","journal-title":"CNS Drugs"},{"key":"12610_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/135245859700300105","volume":"3","author":"A Ghezzi","year":"1997","unstructured":"Ghezzi A, Deplano V, Faroni J et al (1997) Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler 3:43\u201346. https:\/\/doi.org\/10.1177\/135245859700300105","journal-title":"Mult Scler"},{"key":"12610_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamaneurol.2023.4455","volume":"81","author":"P Iaffaldano","year":"2024","unstructured":"Iaffaldano P, Portaccio E, Lucisano G et al (2024) Multiple sclerosis progression and relapse activity in children. JAMA Neurol 81:50\u201358. https:\/\/doi.org\/10.1001\/jamaneurol.2023.4455","journal-title":"JAMA Neurol"},{"key":"12610_CR8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1001\/jamaneurol.2021.1008","volume":"78","author":"D Baroncini","year":"2021","unstructured":"Baroncini D, Simone M, Iaffaldano P et al (2021) Risk of persistent disability in patients with pediatric-onset multiple sclerosis. JAMA Neurol 78:726\u2013735. https:\/\/doi.org\/10.1001\/jamaneurol.2021.1008","journal-title":"JAMA Neurol"},{"key":"12610_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/1352458520930620","volume":"27","author":"A Ghezzi","year":"2021","unstructured":"Ghezzi A, Amato MP, Edan G et al (2021) The introduction of new medications in pediatric multiple sclerosis: open issues and challenges. Mult Scler 27:479\u2013482. https:\/\/doi.org\/10.1177\/1352458520930620","journal-title":"Mult Scler"},{"key":"12610_CR10","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","volume":"379","author":"T Chitnis","year":"2018","unstructured":"Chitnis T, Arnold DL, Banwell B et al (2018) Trial of fingolimod versus interferon beta-1a in PEDIATRIC MULTIPLE SCLEROSIS. N Engl J Med 379:1017\u20131027. https:\/\/doi.org\/10.1056\/NEJMoa1800149","journal-title":"N Engl J Med"},{"key":"12610_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejpn.2023.05.001","volume":"45","author":"AC Saponaro","year":"2023","unstructured":"Saponaro AC, Tully T, Maillart E et al (2023) Treatments of paediatric multiple sclerosis: efficacy and tolerance in a longitudinal follow-up study. Eur J Paediatr Neurol 45:22\u201328. https:\/\/doi.org\/10.1016\/j.ejpn.2023.05.001","journal-title":"Eur J Paediatr Neurol"},{"key":"12610_CR12","doi-asserted-by":"publisher","first-page":"6415","DOI":"10.1007\/s10072-022-06211-8","volume":"43","author":"D Baroncini","year":"2022","unstructured":"Baroncini D, Ghezzi A, Guaschino C et al (2022) Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study. Neurol Sci 43:6415\u20136423. https:\/\/doi.org\/10.1007\/s10072-022-06211-8","journal-title":"Neurol Sci"},{"key":"12610_CR13","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1212\/WNL.0b013e3181f11daf","volume":"75","author":"A Ghezzi","year":"2010","unstructured":"Ghezzi A, Pozzilli C, Grimaldi LM et al (2010) Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 75:912\u2013917. https:\/\/doi.org\/10.1212\/WNL.0b013e3181f11daf","journal-title":"Neurology"},{"key":"12610_CR14","unstructured":"Determina (2020) n. 142638\/2020. GU Serie Generale n.322"},{"key":"12610_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ et al (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375\u2013381. https:\/\/doi.org\/10.1056\/NEJMoa051847","journal-title":"N Engl J Med"},{"key":"12610_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/ane.12718","volume":"136","author":"R Lanzillo","year":"2017","unstructured":"Lanzillo R, Carotenuto A, Moccia M et al (2017) A longitudinal real-life comparison study of natalizumab and fingolimod. Acta Neurol Scand 136:217\u2013222. https:\/\/doi.org\/10.1111\/ane.12718","journal-title":"Acta Neurol Scand"},{"key":"12610_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/1352458516643393","volume":"23","author":"N Koch-Henriksen","year":"2017","unstructured":"Koch-Henriksen N, Magyari M, Sellebjerg F et al (2017) A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. Mult Scler 23:234\u2013241. https:\/\/doi.org\/10.1177\/1352458516643393","journal-title":"Mult Scler"},{"key":"12610_CR18","doi-asserted-by":"publisher","first-page":"699844","DOI":"10.3389\/fneur.2021.699844","volume":"12","author":"M Boziki","year":"2021","unstructured":"Boziki M, Bakirtzis C, Giantzi V et al (2021) Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center. Front Neurol 12:699844. https:\/\/doi.org\/10.3389\/fneur.2021.699844","journal-title":"Front Neurol"},{"key":"12610_CR19","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1177\/1352458520969145","volume":"27","author":"M Cohen","year":"2021","unstructured":"Cohen M, Mondot L, Bucciarelli F et al (2021) BEST-MS: a prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. Mult Scler 27:1556\u20131563. https:\/\/doi.org\/10.1177\/1352458520969145","journal-title":"Mult Scler"},{"key":"12610_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00415-016-8343-5","volume":"264","author":"L Prosperini","year":"2017","unstructured":"Prosperini L, Sacca F, Cordioli C et al (2017) Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naive patients with multiple sclerosis. J Neurol 264:284\u2013294. https:\/\/doi.org\/10.1007\/s00415-016-8343-5","journal-title":"J Neurol"},{"key":"12610_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103012","volume":"53","author":"JB Andersen","year":"2021","unstructured":"Andersen JB, Sharmin S, Lefort M et al (2021) The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. Mult Scler Relat Disord 53:103012. https:\/\/doi.org\/10.1016\/j.msard.2021.103012","journal-title":"Mult Scler Relat Disord"},{"key":"12610_CR22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/1352458513484547","volume":"19","author":"LB Krupp","year":"2013","unstructured":"Krupp LB, Tardieu M, Amato MP et al (2013) International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 19:1261\u20131267. https:\/\/doi.org\/10.1177\/1352458513484547","journal-title":"Mult Scler"},{"key":"12610_CR23","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444\u20131452. https:\/\/doi.org\/10.1212\/wnl.33.11.1444","journal-title":"Neurology"},{"key":"12610_CR24","doi-asserted-by":"publisher","first-page":"e1844","DOI":"10.1212\/WNL.0000000000010414","volume":"95","author":"JD Santoro","year":"2020","unstructured":"Santoro JD, Waltz M, Aaen G et al (2020) Pediatric Multiple Sclerosis Severity Score in a large US cohort. Neurology 95:e1844\u2013e1853. https:\/\/doi.org\/10.1212\/WNL.0000000000010414","journal-title":"Neurology"},{"key":"12610_CR25","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.3390\/app14135626","volume":"14","author":"A Scaravilli","year":"2024","unstructured":"Scaravilli A, Tranfa M, Pontillo G et al (2024) Radiological Reporting Systems in Multiple Sclerosis. Appl Sci 14:5626","journal-title":"Appl Sci"},{"key":"12610_CR26","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/1352458517690821","volume":"23","author":"RH Benedict","year":"2017","unstructured":"Benedict RH, DeLuca J, Phillips G et al (2017) Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler 23:721\u2013733. https:\/\/doi.org\/10.1177\/1352458517690821","journal-title":"Mult Scler"},{"key":"12610_CR27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208114","volume":"102","author":"T Spelman","year":"2024","unstructured":"Spelman T, Simoneau G, Hyde R et al (2024) Comparative effectiveness of natalizumab, fingolimod, and injectable therapies in pediatric-onset multiple sclerosis: a registry-based study. Neurology 102:e208114. https:\/\/doi.org\/10.1212\/WNL.0000000000208114","journal-title":"Neurology"},{"key":"12610_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2217\/nmt-2022-0003","volume":"13","author":"J Foley","year":"2023","unstructured":"Foley J, Berkovich R, Gudesblatt M et al (2023) Characterizing the \u201cfeel-good experience\u201d in multiple sclerosis patients treated with natalizumab or other therapies. Neurodegener Dis Manag 13:23\u201334. https:\/\/doi.org\/10.2217\/nmt-2022-0003","journal-title":"Neurodegener Dis Manag"},{"key":"12610_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058643","volume":"8","author":"A Svenningsson","year":"2013","unstructured":"Svenningsson A, Falk E, Celius EG et al (2013) Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting. PLoS ONE 8:e58643. https:\/\/doi.org\/10.1371\/journal.pone.0058643","journal-title":"PLoS ONE"},{"key":"12610_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1468-1331.2010.03112.x","volume":"18","author":"S Belachew","year":"2011","unstructured":"Belachew S, Phan-Ba R, Bartholome E et al (2011) Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 18:240\u2013245. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03112.x","journal-title":"Eur J Neurol"},{"key":"12610_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105669","volume":"87","author":"S Jafarpour","year":"2024","unstructured":"Jafarpour S, Pinto S, Vu MH et al (2024) Delayed initiation of disease modifying therapy increases relapse frequency and motor disability in pediatric onset multiple sclerosis. Mult Scler Relat Disord 87:105669. https:\/\/doi.org\/10.1016\/j.msard.2024.105669","journal-title":"Mult Scler Relat Disord"},{"key":"12610_CR32","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001008","author":"OA Abdel-Mannan","year":"2021","unstructured":"Abdel-Mannan OA, Manchoon C, Rossor T et al (2021) Use of disease-modifying therapies in pediatric relapsing-remitting multiple sclerosis in the United Kingdom. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000001008","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12610_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25737","volume":"88","author":"KM Krysko","year":"2020","unstructured":"Krysko KM, Graves JS, Rensel M et al (2020) Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis. Ann Neurol 88:42\u201355. https:\/\/doi.org\/10.1002\/ana.25737","journal-title":"Ann Neurol"},{"key":"12610_CR34","first-page":"90","volume":"16","author":"M Trojano","year":"2009","unstructured":"Trojano M, Pellegrini F, Paolicelli D et al (2009) Observational studies: propensity score analysis of non-randomized data. Int MS J 16:90\u201397","journal-title":"Int MS J"},{"key":"12610_CR35","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/ana.24339","volume":"77","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Horakova D, Spelman T et al (2015) Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol 77:425\u2013435. https:\/\/doi.org\/10.1002\/ana.24339","journal-title":"Ann Neurol"},{"key":"12610_CR36","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/jnnp-2015-310597","volume":"87","author":"JA Cohen","year":"2016","unstructured":"Cohen JA, Khatri B, Barkhof F et al (2016) Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry 87:468\u2013475. https:\/\/doi.org\/10.1136\/jnnp-2015-310597","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12610_CR37","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/jnnp-2019-322138","volume":"91","author":"DL Arnold","year":"2020","unstructured":"Arnold DL, Banwell B, Bar-Or A et al (2020) Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study. J Neurol Neurosurg Psychiatry 91:483\u2013492. https:\/\/doi.org\/10.1136\/jnnp-2019-322138","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12610_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10072-021-05116-2","volume":"42","author":"G Borriello","year":"2021","unstructured":"Borriello G, Pozzilli C (2021) Long-term fingolimod treatment in two pediatric patients with multiple sclerosis. Neurol Sci 42:29\u201336. https:\/\/doi.org\/10.1007\/s10072-021-05116-2","journal-title":"Neurol Sci"},{"key":"12610_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2021-000215","volume":"4","author":"L Krupp","year":"2022","unstructured":"Krupp L, Banwell B, Chitnis T et al (2022) Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study. BMJ Neurol Open 4:e000215. https:\/\/doi.org\/10.1136\/bmjno-2021-000215","journal-title":"BMJ Neurol Open"},{"key":"12610_CR40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/jnnp-2019-321124","volume":"91","author":"K Deiva","year":"2020","unstructured":"Deiva K, Huppke P, Banwell B et al (2020) Consistent control of disease activity with fingolimod versus IFN beta-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS. J Neurol Neurosurg Psychiatry 91:58\u201366. https:\/\/doi.org\/10.1136\/jnnp-2019-321124","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12610-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12610-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12610-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T03:53:53Z","timestamp":1727927633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12610-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["12610"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12610-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AC has received research grants from Almirall, research grants from ECTRIMS-MAGNIMS and honoraria from Almirall, Biogen, Roche, Sanofi-Genzyme, Merck, Ipsen and Novartis. MM has received research grants from the ECTRIMS-MAGNIMS, the UK MS Society, and Merck; honoraria from Biogen, BMS Celgene, Ipsen, Janssen, Merck, Novartis, Roche, and Sanofi-Genzyme. MP has received research grants from Italian MS Foundation and Baroni Foundation, honoraria from HEALTH&LIFE S.r.l. and Biogen and sponsorship for travel\/meeting expenses from Novartis, Roche and Merck. RL has received honoraria from Biogen, Merck, Novartis, Roche, and Teva. VBM has received research grants from the Italian MS Society, and Roche, and honoraria from Bayer, Biogen, Merck, Mylan, Novartis, Roche, Sanofi-Genzyme, and Teva. MV has received grants by Biogen, Roche, Lusofarmaco and Angelini. ALS, CDM, FN, DDS, CI, GS, LP, GDL, CM, MT have nothing to disclose. VT has received research and travel support and honoraria from the Biogen, BMS Celgene, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme Almirall, Viatris, Lundbeck. Carlo Pozzilli has served on scientific advisory boards for Bristol Meyer, Novartis, Merck, Biogen, Roche, Janssen, Alexion, Almirall and has received research support from Merck, Biogen, Bristol Meyer, Novartis and Roche. AI received consulting fees from Janssen. ES received personal compensation from Almirall, Biogen, Sanofi, Novartis, Roche, Horizon, Alexion, Merck, Mylan and Teva for traveling and advisory boards. GB received honoraria and consulting fees from Almirall, Biogen, BMS, Janssen, Merck, Novartis, Sanofi and Roche. GL received speaker honoraria and\/or consultancy from Biogen, Teva, Genzyme, Merck, Novartis, Almirall and Roche. EP received compensation for travel grants, participation in advisory board and\/or speaking activities from Biogen, Merck Serono, Sanofi, Teva, and Novartis; serves on the editorial board of Frontiers in Neurology and Brain Sciences. MPA served on scientific advisory boards for and has received speaker honoraria and research support from Biogen Idec, Merck Serono, Bayer Schering Pharma, and Sanofi Aventis, and serves on the editorial board of Multiple Sclerosis Journal and BMC Neurology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}